CA3142876A1 - Telmisartan for the treatment of chronic kidney disease in dogs - Google Patents

Telmisartan for the treatment of chronic kidney disease in dogs Download PDF

Info

Publication number
CA3142876A1
CA3142876A1 CA3142876A CA3142876A CA3142876A1 CA 3142876 A1 CA3142876 A1 CA 3142876A1 CA 3142876 A CA3142876 A CA 3142876A CA 3142876 A CA3142876 A CA 3142876A CA 3142876 A1 CA3142876 A1 CA 3142876A1
Authority
CA
Canada
Prior art keywords
telmisartan
period
treatment
upc
daily dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3142876A
Other languages
English (en)
French (fr)
Inventor
Anne Michelle Traas
Coleman Amanda Erickson
Bianca Natalia Ferreira De Moura Lourenco
Kate Elizabeth Creevy
Scott Alan Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica GmbH
University of Georgia Research Foundation Inc
Original Assignee
Boehringer Ingelheim Vetmedica GmbH
University of Georgia Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica GmbH, University of Georgia Research Foundation Inc filed Critical Boehringer Ingelheim Vetmedica GmbH
Publication of CA3142876A1 publication Critical patent/CA3142876A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3142876A 2019-07-09 2020-04-30 Telmisartan for the treatment of chronic kidney disease in dogs Pending CA3142876A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962871752P 2019-07-09 2019-07-09
US62/871,752 2019-07-09
PCT/US2020/030579 WO2021006941A1 (en) 2019-07-09 2020-04-30 Telmisartan for the treatment of chronic kidney disease in dogs

Publications (1)

Publication Number Publication Date
CA3142876A1 true CA3142876A1 (en) 2021-01-14

Family

ID=70775531

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3142876A Pending CA3142876A1 (en) 2019-07-09 2020-04-30 Telmisartan for the treatment of chronic kidney disease in dogs

Country Status (10)

Country Link
US (1) US20220218671A1 (https=)
EP (1) EP3996705A1 (https=)
JP (2) JP2022540074A (https=)
KR (1) KR20220054291A (https=)
CN (1) CN114450004A (https=)
BR (1) BR112022000315A2 (https=)
CA (1) CA3142876A1 (https=)
MX (1) MX2022000429A (https=)
TW (1) TW202116305A (https=)
WO (1) WO2021006941A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220054292A (ko) 2019-07-09 2022-05-02 베링거잉겔하임베트메디카게엠베하 개의 고혈압 치료를 위한 텔미사르탄

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3648761T (pt) 2017-07-07 2024-06-05 Boehringer Ingelheim Vetmedica Gmbh Telmisartan para a profilaxia ou tratamento de hipertensão em gatos

Also Published As

Publication number Publication date
US20220218671A1 (en) 2022-07-14
EP3996705A1 (en) 2022-05-18
KR20220054291A (ko) 2022-05-02
JP2022540074A (ja) 2022-09-14
BR112022000315A2 (pt) 2022-02-22
CN114450004A (zh) 2022-05-06
AU2020311280A1 (en) 2022-02-24
TW202116305A (zh) 2021-05-01
JP2025120167A (ja) 2025-08-15
WO2021006941A1 (en) 2021-01-14
MX2022000429A (es) 2022-04-25

Similar Documents

Publication Publication Date Title
JP6337170B2 (ja) ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト
JP2025156428A (ja) ネコの糖尿病を管理する化合物
JP2025120167A (ja) イヌの慢性腎臓病の治療のためのテルミサルタン
JP2025115405A (ja) イヌの高血圧の治療のためのテルミサルタン
Jepson et al. Management of chronic kidney disease
US10905676B2 (en) Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
AU2020311280B2 (en) Telmisartan for the treatment of chronic kidney disease in dogs
US20250195525A1 (en) Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats
RU2832966C2 (ru) Телмисартан для лечения хронической болезни почек у собак
EA026713B1 (ru) Твердая пероральная лекарственная форма для лечения дефицита железа или анемии и ее применение
AU2020310059B2 (en) Telmisartan for the treatment of hypertension in dogs
RU2830555C2 (ru) Телмисартан для лечения гипертонии у собак
AU2026202684A1 (en) Telmisartan for the treatment of hypertension in dogs
CN117396197A (zh) 慢性肾脏病的猫的治疗方法
Torres Feline Chronic Kidney Disease
Leaver et al. Critical appraisal of medical and dietary treatments of proteinuria in dogs and cats.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240320

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20250313

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250326

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250422

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250422

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250728

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260420

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260420